FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
IDEXX Laboratories, Inc. Stock AnalysisComprehensive stock analysis for IDEXX Laboratories, Inc. (IDXX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisIDXX
IDXX
IDEXX Laboratories, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
IDXX
Home🔹Stocks🔹IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.

🇺🇸IDXX•NASDAQ

IDEXX Laboratories, Inc.

🇺🇸IDXX•NASDAQ
Market cap
$39.81B
Sentiment

Your view on IDXX

Mkt Cap
$39.81B
Sentiment
Your view
IDXX
IDEXX Laboratories, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
IDXX
Company Overview

Overview

What the company does, where it operates, and who runs it.

About IDEXX Laboratories, Inc.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Jonathan J. Mazelsky
Headquarters
One IDEXX Drive, Westbrook, ME, US
Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Jonathan J. Mazelsky
Headquarters
One IDEXX Drive, Westbrook, ME, US
Description

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments.

It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.

The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits.

In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups.

The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for IDEXX Laboratories, Inc., and the rating behind it. IDXX last traded at $504.70, 35.3× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for IDEXX Laboratories, Inc.. Starting points for IDEXX Laboratories, Inc.: P/E 35.3, EPS $14.23, beta 1.54 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for IDEXX Laboratories, Inc.. IDEXX Laboratories, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for IDEXX Laboratories, Inc.. Trailing twelve-month EPS for IDEXX Laboratories, Inc. stands at $14.23. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for IDEXX Laboratories, Inc.. IDEXX Laboratories, Inc. has reported as a listed company since 1991. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

IDEXX Laboratories, Inc. valued side by side against its closest peers. IDEXX Laboratories, Inc. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold IDEXX Laboratories, Inc., and how their positions are changing. At a $39.81B market value, institutional positions materially move IDEXX Laboratories, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by IDEXX Laboratories, Inc. executives and directors. Shares of IDEXX Laboratories, Inc. have traded between $356.14 and $735.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming IDEXX Laboratories, Inc.. IDEXX Laboratories, Inc. is a $39.81B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming IDEXX Laboratories, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for IDEXX Laboratories, Inc.. Coverage tracks IDEXX Laboratories, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • A — Agilent Technologies, Inc.
  • ALNY — Alnylam Pharmaceuticals, Inc.
  • ARGX — argenx SE
  • BDX — Becton, Dickinson and Company
  • CAH — Cardinal Health, Inc.
  • COR — Cencora, Inc.
  • EW — Edwards Lifesciences Corporation
  • IQV — IQVIA Holdings Inc.

More Medical - Diagnostics & Research companies

  • MRPS — Microphonics, Inc.
  • MTD — Mettler-Toledo International Inc.
  • MVF.AX — Monash IVF Group Limited
  • MYGN — Myriad Genetics, Inc.
  • NDRA — ENDRA Life Sciences Inc.
  • NEO — NeoGenomics, Inc.
  • NSTM — NovelStem International Corp.
  • NTRA — Natera, Inc.
  • OCLG — Oncologix Tech, Inc.
  • OPK — OPKO Health, Inc.
  • PEB.AX — Pacific Edge Limited
  • PFGTF — Pacific Edge Limited

ETFs holding IDEXX Laboratories, Inc.

  • PAWZ — ProShares Pet Care ETF (9.71%)
  • PHO — Invesco Water Resources ETF (6.04%)
  • PFOE — Pathfinder Focused Opportunities ETF (4.73%)
  • IHI — iShares US Medical Devices ETF (4.02%)

News

Latest Market News